QDEL logo

QUIDELORTHO CORP

QDELNASDAQ
πŸ† #2080 by market capEarnings Nov 3US Equity
$952.40β–Ό $18.19 (βˆ’1.91%)
Simulated price
1hβ€”
24hβ–Ό 1.9%
7dβ€”
14dβ€”
30dβ€”
1yβ€”
🏦Market Cap
$954M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-1.9%
Declining
πŸ“ŠGross Margin
44.6%
Healthy
πŸ’΅FCF Margin
-7.9%
Thin
βš–οΈP/S Ratio
0.4x
Cheap
Otter Score
54
Weak
No chart data available for QDEL.

Trading Snapshot

Day Range
$943.14 – $962.55
52-Week Range
$9.92 – $35.58
Volume
$5.95B
Avg Volume
$7.51B
Shares Outstanding
68.2M
Next Earnings
Aug 31, 2026

Fundamentals Snapshot

Annual Revenue
$2.73B
Last Q Revenue
$631M
P/E Ratio
-0.9
P/S Ratio
0.4x
EPS (TTM)
$-15.35
Dividend Yield
0.00%

Why Investors Own QDEL

  • βœ“High-growth profile β€” revenue up +36.5% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 70% gross margin and 17% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$2.73Bβ–² +37.7% YoY
Gross Margin (TTM)
69.9%β–² +4.4% YoY
Operating Income (TTM)
$614Mβ–² +37.7% YoY
Free Cash Flow (TTM)
$464Mβ–² +37.7% YoY

About QUIDELORTHO CORP

QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
54/100

Analyst Price Target

β“˜
Average Target
$1,102.00
β–² +15.7% Upside
High Target$1,323.85
Low Target$826.97
Based on 11 analysts

Latest News & Updates